Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMA401 in recurrent and/or refractory solid tumors
NCT05359445Phase 1Active, not recruiting
- Sponsor
- Immatics
- Start
- May 2022
- Primary completion
- Mar 2026
- Modality
- Recombinant Proteins and Enzymes, Bispecific Antibodies, Peptides
- Countries
- 1
01
Overview
Phase 1, open-label trial of IMA401 in solid tumor, non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC) (3 arms), sponsored by Immatics. Primary endpoint: Number of patients with dose limiting toxicities at 44 months. Started May 2022; status: active, not recruiting.
02
Drugs
IMA401
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT05359445.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05359445.